Cargando…

Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease

Chronic graft versus host disease (cGVHD) is a debilitating and costly complication following haemopoietic stem cell transplantation (HSCT). This study describes the economic burden associated with cGVHD. Direct costs associated with specialised healthcare utilisation (inpatient admissions and outpa...

Descripción completa

Detalles Bibliográficos
Autores principales: Schain, Frida, Batyrbekova, Nurgul, Liwing, Johan, Baculea, Simona, Webb, Thomas, Remberger, Mats, Mattsson, Jonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822787/
https://www.ncbi.nlm.nih.gov/pubmed/33275188
http://dx.doi.org/10.1007/s10198-020-01249-x
_version_ 1783639703978770432
author Schain, Frida
Batyrbekova, Nurgul
Liwing, Johan
Baculea, Simona
Webb, Thomas
Remberger, Mats
Mattsson, Jonas
author_facet Schain, Frida
Batyrbekova, Nurgul
Liwing, Johan
Baculea, Simona
Webb, Thomas
Remberger, Mats
Mattsson, Jonas
author_sort Schain, Frida
collection PubMed
description Chronic graft versus host disease (cGVHD) is a debilitating and costly complication following haemopoietic stem cell transplantation (HSCT). This study describes the economic burden associated with cGVHD. Direct costs associated with specialised healthcare utilisation (inpatient admissions and outpatient visits), as well as indirect costs associated with sickness absence-associated productivity loss were estimated in patients who underwent allogeneic HSCT in Sweden between 2006 and 2015, linking population-based health and economic registers. To capture the period of chronic GVHD, patients were included who survived > 182 days post-HSCT (start of follow-up), and cGVHD was classified based on patient treatment records to correct for any diagnosis underreporting. Patients were classified as ‘non-cGVHD’ if they received no immunosuppressive treatment, ‘mild cGVHD’ if they received only systemic corticosteroid treatment or immunosuppressive treatment, or ‘moderate–severe cGVHD’ if they received extracorporeal photopheresis (ECP) only, corticosteroid treatment and immunosuppressive treatment, or systemic corticosteroid treatment and ECP treatments. Patients with moderate–severe cGVHD spent more time in healthcare, had higher healthcare resource costs and higher sickness absence-related productivity loss compared to patients with non- or mild cGVHD. The cumulative total costs during the first 3 years of follow-up were EUR 14,887,599, EUR 20,544,056, and EUR 47,811,835 for non-, mild, and moderate–severe groups, respectively. The long-term costs incurred with cGVHD following HSCT continue to be very high and significantly impacted by cGVHD severity. This study adds real-world health resource and economic insight relevant for policy-makers and healthcare providers when considering the clinical challenge of balancing immunosuppression to reduce cGVHD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10198-020-01249-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7822787
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-78227872021-02-11 Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease Schain, Frida Batyrbekova, Nurgul Liwing, Johan Baculea, Simona Webb, Thomas Remberger, Mats Mattsson, Jonas Eur J Health Econ Original Paper Chronic graft versus host disease (cGVHD) is a debilitating and costly complication following haemopoietic stem cell transplantation (HSCT). This study describes the economic burden associated with cGVHD. Direct costs associated with specialised healthcare utilisation (inpatient admissions and outpatient visits), as well as indirect costs associated with sickness absence-associated productivity loss were estimated in patients who underwent allogeneic HSCT in Sweden between 2006 and 2015, linking population-based health and economic registers. To capture the period of chronic GVHD, patients were included who survived > 182 days post-HSCT (start of follow-up), and cGVHD was classified based on patient treatment records to correct for any diagnosis underreporting. Patients were classified as ‘non-cGVHD’ if they received no immunosuppressive treatment, ‘mild cGVHD’ if they received only systemic corticosteroid treatment or immunosuppressive treatment, or ‘moderate–severe cGVHD’ if they received extracorporeal photopheresis (ECP) only, corticosteroid treatment and immunosuppressive treatment, or systemic corticosteroid treatment and ECP treatments. Patients with moderate–severe cGVHD spent more time in healthcare, had higher healthcare resource costs and higher sickness absence-related productivity loss compared to patients with non- or mild cGVHD. The cumulative total costs during the first 3 years of follow-up were EUR 14,887,599, EUR 20,544,056, and EUR 47,811,835 for non-, mild, and moderate–severe groups, respectively. The long-term costs incurred with cGVHD following HSCT continue to be very high and significantly impacted by cGVHD severity. This study adds real-world health resource and economic insight relevant for policy-makers and healthcare providers when considering the clinical challenge of balancing immunosuppression to reduce cGVHD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10198-020-01249-x) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-12-04 2021 /pmc/articles/PMC7822787/ /pubmed/33275188 http://dx.doi.org/10.1007/s10198-020-01249-x Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Schain, Frida
Batyrbekova, Nurgul
Liwing, Johan
Baculea, Simona
Webb, Thomas
Remberger, Mats
Mattsson, Jonas
Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
title Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
title_full Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
title_fullStr Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
title_full_unstemmed Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
title_short Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
title_sort real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822787/
https://www.ncbi.nlm.nih.gov/pubmed/33275188
http://dx.doi.org/10.1007/s10198-020-01249-x
work_keys_str_mv AT schainfrida realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease
AT batyrbekovanurgul realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease
AT liwingjohan realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease
AT baculeasimona realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease
AT webbthomas realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease
AT rembergermats realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease
AT mattssonjonas realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease